Evaluation of point-of-care instrument for quantification of infliximab and adalimumab
We find the efficacy and accuracy of the ProciseDx acceptable, but when performed by non-laboratory personnel, the differences to routine measurements are considerable and could have a clinical impact. Clinical implementation would at least require reevaluation of the therapeutic intervals.
Authors
- Karina Vogn Koch
- Torben Knudsen (ORCID: https://orcid.org/0000-0003-0726-0115)
- Mads Nybo (ORCID: https://orcid.org/0000-0002-3029-2855)
- Morten Beck Trelle (ORCID: https://orcid.org/0000-0002-5220-4297)
- Mark Ainsworth (ORCID: https://orcid.org/0000-0002-4899-1048)
Institutions
- Odense University Hospital (DK)
- Hospital South West Jutland (DK)
- Svendborg Sygehus (DK)
Publication Details
- Journal
- Scandinavian Journal of Clinical and Laboratory Investigation
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1080/00365513.2025.2559355
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00